Galectin Therapeutics Inc. Share Price
GALTGalectin Therapeutics Inc. Stock Performance
Open $3.02 | Prev. Close $2.96 | Circuit Range N/A |
Day Range $2.95 - $3.02 | Year Range $1.11 - $7.13 | Volume 22,357 |
Average Traded $2.98 |
Galectin Therapeutics Inc. Share Price Chart
About Galectin Therapeutics Inc.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Galectin Therapeutics Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
16-Jan-26 | $3.10 | $3.04 | -3.64% |
15-Jan-26 | $3.07 | $3.16 | +5.33% |
14-Jan-26 | $3.04 | $3.00 | -2.44% |
13-Jan-26 | $3.17 | $3.08 | -2.54% |
12-Jan-26 | $3.14 | $3.15 | +0.16% |
09-Jan-26 | $3.06 | $3.15 | -1.41% |
08-Jan-26 | $3.53 | $3.19 | -9.75% |